Akums Drugs and Pharmaceuticals cash flow

Latest FY26
Cash from operations
₹1,181cr+153.9% on FY25
Capital spending
₹231cr−15.3% on FY25
Free cash flow
₹951cr+392.9% on FY25
Cash from financing
₹33.9cr−53.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—155153
—94.134.6
—0.0−3.9
—0.01.6
—0.1−3.5
—−3.8−16.8
Changes in working capital
—−74.8−50.6
—−55.734.1
—−78.3−49.3
—−26.6119
—6.962.6
—51.533.3
Cash from operating activities
426382345
—68.1315
—450660
—−110−25.0
—928−86.7
—87.483.2
—1,181465
Cash from investing activities
—231272
—7.78.5
—38.725.0
—−746−309
—−930−548
Cash from financing activities
—0.0637
—59.3−354
—0.0124
—16.358.4
—9.128.3
—33.972.8
—285−9.9
—285−9.9
Reference items
568522464
12.6%12.0%11.3%
951951193
—1,001—
₹62.09₹62.09₹12.60
11.93×——
—4.61×1.35×
—87.483.2
—9.128.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,346 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation153.4154.6—
+ Finance Costs34.694.1—
+ Fair Value (Gains) / Losses-3.90.0—
+ Share-based Payments1.60.0—
+ Other Non-cash Items-3.50.1—
+ Other Reconciling Items-16.8-3.8—
Changes in Working Capital
+ Inventories-50.6-74.8—
+ Trade Receivables — Current34.1-55.7—
+ Other Current Assets-49.3-78.3—
+ Trade Payables — Current119.2-26.6—
+ Other Financial Liabilities — Current62.66.9—
+ Provisions — Current33.351.5—
Cash from Operating Activities
Profit Before Tax (per I/S)345.3382.1425.7
+ Total Adjustments (incl. Working Capital)314.868.1—
Cash from Operations (pre-tax)660.1450.2—
+ Interest Received — Operating-25.0-109.7—
+ Other Inflows / (Outflows) — Operating-86.7928.1—
+ Income Taxes Paid83.287.4—
Cash from Operating Activities465.21,181.2—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)272.3230.5—
+ Disp of Fixed Assets8.57.7—
+ Interest Received — Investing25.038.7—
+ Other Inflows / (Outflows) — Investing-309.1-746.1—
Cash from Investing Activities-547.8-930.3—
Cash from Financing Activities
+ Proceeds from Issue of Shares637.40.0—
+ Proceeds from Borrowings-354.059.3—
+ Repayment of Borrowings123.90.0—
+ Payment of Lease Liabilities58.416.3—
+ Interest Paid28.39.1—
Cash from Financing Activities72.833.9—
Net Changes in Cash (pre-FX)-9.9284.8—
Net Changes in Cash-9.9284.8—
Reference Items
EBITDA464.5522.0567.7
EBITDA Margin %11.2811.9812.61
Free Cash Flow (CFO − Capex)192.9950.7950.7
Free Cash Flow to Equity—1,000.8—
Free Cash Flow per Basic Share12.6062.0962.09
Price to Free Cash Flow——11.93
Cash Flow to Net Income1.354.61—
Cash Paid for Taxes83.287.4—
Cash Paid for Interest28.39.1—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.